Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$77.3 million.
- Inhibikase Therapeutics' Enterprise Value fell 228380.57% to -$77.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.3 million, marking a year-over-year decrease of 228380.57%. This contributed to the annual value of -$97.5 million for FY2024, which is 63606.36% down from last year.
- According to the latest figures from Q3 2025, Inhibikase Therapeutics' Enterprise Value is -$77.3 million, which was down 228380.57% from -$87.7 million recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Enterprise Value registered a high of -$3.2 million during Q3 2024, and its lowest value of -$97.5 million during Q4 2024.
- Moreover, its 5-year median value for Enterprise Value was -$26.5 million (2022), whereas its average is -$37.6 million.
- As far as peak fluctuations go, Inhibikase Therapeutics' Enterprise Value tumbled by 60152563.9% in 2021, and later surged by 8072.88% in 2024.
- Over the past 5 years, Inhibikase Therapeutics' Enterprise Value (Quarter) stood at -$40.8 million in 2021, then surged by 43.44% to -$23.1 million in 2022, then soared by 42.51% to -$13.3 million in 2023, then tumbled by 636.06% to -$97.5 million in 2024, then rose by 20.73% to -$77.3 million in 2025.
- Its Enterprise Value stands at -$77.3 million for Q3 2025, versus -$87.7 million for Q2 2025 and -$93.2 million for Q1 2025.